We will be contrasting the differences between CRISPR Therapeutics AG (NASDAQ:CRSP) and BioNTech SE (NASDAQ:BNTX) as far as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||60||0.00||34.37M||-0.46||0.00|
Table 1 demonstrates CRISPR Therapeutics AG and BioNTech SE’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 provides us CRISPR Therapeutics AG and BioNTech SE’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,235,636.97%||-2.6%||-2%|
CRISPR Therapeutics AG has a Current Ratio of 8.3 and a Quick Ratio of 8.3. Competitively, BioNTech SE’s Current Ratio is 3.7 and has 3.7 Quick Ratio. CRISPR Therapeutics AG’s better ability to pay short and long-term obligations than BioNTech SE.
In next table is shown CRISPR Therapeutics AG and BioNTech SE’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
CRISPR Therapeutics AG’s upside potential is 8.55% at a $72 consensus target price. Competitively BioNTech SE has an average target price of $22.17, with potential downside of -36.66%. Based on the data shown earlier, CRISPR Therapeutics AG is looking more favorable than BioNTech SE, analysts opinion.
Institutional & Insider Ownership
Institutional investors owned 46.8% of CRISPR Therapeutics AG shares and 0% of BioNTech SE shares. Insiders owned roughly 0.4% of CRISPR Therapeutics AG’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
For the past year CRISPR Therapeutics AG has stronger performance than BioNTech SE
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.